source
- Another Paragon offshoot chooses reverse merger, this time for migraine drugsThey say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the p…Endpoints · 2mo ago↗ source
- Acceleron leaders and Westlake jumpstart new IPF biotechAfter success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round,…Endpoints · 2mo ago↗ source
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.